Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster
Naoko Shoji(Pharmaceuticals and Medical Devices Agency), Ayano Sasaki(Pharmaceuticals and Medical Devices Agency), Keiji Tanese(Toho University), Taishi Horiuchi(Pharmaceuticals and Medical Devices Agency), Wataru Asakura(Pharmaceuticals and Medical Devices Agency), Koichi Fukuda(National Institute of Advanced Industrial Science and Technology), Yuji Utsuno(Pharmaceuticals and Medical Devices Agency), Hirofumi Minami(Pharmaceuticals and Medical Devices Agency), Yukiko Hoshino(Pharmaceuticals and Medical Devices Agency), Shinichi Noda(Pharmaceuticals and Medical Devices Agency)
Cited by 25
Related Papers
Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy
|Oncotarget|2016|160
Diagnosis and Management of Basal Cell Carcinoma
|Current Treatment Options in Oncology|2019|153
G-Protein-Coupled Receptor GPR49 is Up-regulated in Basal Cell Carcinoma and Promotes Cell Proliferation and Tumor Formation
|American Journal Of Pathology|2008|141
IRAK‐M mediates Toll‐like receptor/IL‐1R‐induced NFκB activation and cytokine production
|The EMBO Journal|2013|141
Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ
|Journal of Investigative Dermatology|2015|95